Please login to the form below

Not currently logged in
Email:
Password:

SGLT2

This page shows the latest SGLT2 news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The CHMP decision is based on the results of the CANVAS programme, the largest completed CV outcomes trial to date for any of the SGLT2 inhibitors. ... The first SGLT2 inhibitor to gain this EU label update was Boehringer and Lilly’s.

Latest news

More from news
Approximately 9 fully matching, plus 68 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Figure 1 (pictured right) shows the position of the DPP4/SGLT2 market for the last four months to March 2017 in English GP practices compared to the previous Tertial (four months). ... In contrast Jardiance and Vipidia are still growing where Jardiance

  • Deal Watch November 2015 Deal Watch November 2015

    Sotagliflozin is an oral dual inhibitor of sodium-glucose cotransporters type 1 and 2 (SGLT1 &SGLT2) which are responsible for glucose reabsorption by the GI tract and kidney respectively.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.

  • Back to the future Back to the future

    The introduction of a wave of SGLT2 inhibitors will further energise the market - with Novo Nordisk, J&J, Lily, Boehringer, AZ, Merck and Pfizer all due to compete in this space.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    the way SGLT2 inhibitors work by reducing the amount of glucose absorbed in the kidney and passing it out through urine. “ ... The potential for the SGLT2 class of treatments which Forxiga is the first to launch, is tremendous.”.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics